Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
- 25 October 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (23), 14276-14307
- https://doi.org/10.1021/acs.jmedchem.0c01013
Abstract
Certain subtypes of cancer cells require oxidative phosphorylation (OXPHOS) to survive. Increased OXPHOS dependency is frequently a hallmark of cancer stem cells and cells resistant to chemotherapy and targeted therapies. Suppressing the OXPHOS function might also influence the tumor microenvironment by alleviating hypoxia and improving the antitumor immune response. Thus, targeting OXPHOS is a promising strategy to treat various cancers. A growing arsenal of therapeutic agents is under development to inhibit this biological process. This Perspective provides an overview of the structure and function of OXPHOS complexes, their biological functions in cancer, relevant research tools and models, as well as the limitations of OXPHOS as drug targets. We also focus on the current development status of OXPHOS inhibitors and potential therapeutic strategies to strengthen their clinical applications.Keywords
Funding Information
- National Institutes of Health (R01 CA188252)
This publication has 275 references indexed in Scilit:
- Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease HeterogeneityEuropean Urology, 2013
- Respiratory chain complex I deficiency caused by mitochondrial DNA mutationsEuropean Journal of Human Genetics, 2011
- The quinone-binding and catalytic site of complex IIBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2010
- Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysisNature Biotechnology, 2010
- Single Agents with Designed Combination Chemotherapy Potential: Synthesis and Evaluation of Substituted Pyrimido[4,5-b]indoles as Receptor Tyrosine Kinase and Thymidylate Synthase Inhibitors and as Antitumor AgentsJournal of Medicinal Chemistry, 2010
- Cardioprotection by metabolic shut-down and gradual wake-upJournal of Molecular and Cellular Cardiology, 2009
- The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channelsBasic Research in Cardiology, 2009
- Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell ProliferationMolecular Cell, 2009
- The endogenous mitochondrial complex II inhibitor malonate regulates mitochondrial ATP-sensitive potassium channels: Implications for ischemic preconditioningBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2008
- Crystallographic studies of the binding of ligands to the dicarboxylate site of Complex II, and the identity of the ligand in the “oxaloacetate-inhibited” stateBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2006